Drug intelligence / Profile preview

eclitasertib

Development stage: Phase 2
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Eclitasertib (SAR443122, DNL758) is an orally bioavailable small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It is under development as an immunomodulatory drug for inflammatory and autoimmune diseases. Eclitasertib disrupts RIPK1-mediated signaling, which plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition. By inhibiting RIPK1 kinase activity, the drug aims to attenuate inflammation and limit tissue damage. Clinical trials have investigated its use in severe COVID-19, cutaneous lupus erythematosus, and ulcerative colitis[4][5]. The primary developer is Sanofi[7].

Other names: eclitasertib

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on eclitasertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eclitasertib.

Explore the full profile